RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Moved up those "pinks" at the last one minuteThe big difference is that Esperion succeeded in hitting their endpoints in all of their various Phase 2s, whereas Resverlogix missed the mark in Phase 2 ASSURE. Esperion is proceeding to Phase 3 from a consistent hypothesis, mechanism of action, and achievement. Resverlogix's hypothesis, MOA and achievements have been on a windy and bumpy road that at times seemed to be a dead end. Phase 3 BETonMACE is based upon post-hoc analysis of two Phase 2 trials, one of which failed to meet its endpoint. And, the post-hoc was done on 5-point MACE, whereas the BETonMACE endpoint is 3-point MACE. Both companies have blockbuster potential, don't get me wrong. But one of the two companies still has a lot more to prove than the other from a clinical trial perspective.
BearDownAZ